Current potentials for the drug therapy of adrenocortical cancer
- Autores: Filimonyuk A.V1
-
Afiliações:
- Edição: Nº 18 (2012)
- Páginas: 10-14
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279992
- ID: 279992
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Adrenocortical cancer (ACC) is a rare malignancy for which guidelines for drug therapy have not yet developed. This review presents the current potentials for the chemotherapy of ACC; analysis of the effectiveness of different drugs and their combinations was performed. The advisability of use of EDP-M scheme, including mitotane in combination with etoposide, doxorubicin and cisplatin, for the treatment of ACC is explained.
Palavras-chave
Texto integral
Bibliografia
- Бритвин T.A., Калинин A.П., Пирогов Д.А. Aдренокортикальный рак (современное состояние проблемы) // Сибирский медицинский журнал 200S. № б. С. 13-S.
- Сельчук B.Ю., Баронин A.A., Филимонюк A.B. Первичные и метастатические опухоли надпочечников // РМЖ 2005. Т 13 (онкология). № 13. С. 2-14.
- Филимонюк А.В., Тедорадзе Р.В., Шарнов М.Б. и др. Современные аспекты в диагностике и лечении адренокортикального рака // Кремлевская медицина. Клинический вестник 2011. № 4. C. 86-90.
- Allolio B., Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
- Phan A.T. Adrenal cortical carcinoma - review of current knowledge and treatment practices.Hematol Oncol Clin North Am 2007;21: 489-507.
- Roman S. Adrenocortical carcinoma. Curr Opin Oncol 2006;18:36-42.
- Bilimoria K.Y., Shen W.T., Elaraj D., et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008;113:3130-3016.
- Kirschner L.S. Editorial: paradigms for adrenal cancer: think globally, act locally. J Clin Endocrinol Metab 2006;91:4250-52.
- Abiven G., Coste J., Groussin L., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-55.
- Malandrino P., Al Ghuzlan A., Castaing M., et al. Prognostic markers of survival after combined mitotane- and platinum-chemotherapy in metastatic adrenocortical carcinoma. Endocr Related Cancers 2010;17: 797-807.
- Baudin E., Docao C., Gicquel C., et al. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 2002;13:1806-809.
- Khan T.S., Imam H., Juhlin C., et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-87.
- Berruti A., Terzolo M., Sperone P. et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66.
- Fassnacht M., Terzolo M., Allolio B., et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366(23):2189-97.
- Abraham J., Bakke S., Rutt A., et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-43.
- Khan T.S., Sundin A., Juhlin C., et al. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol 2004;21:167-77.
- Quinkler M., Hahner S., Wortmann S., et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008;93:2057-62.
- Wortmann S., Quinkler M., Ritter C., et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010;162:349-56.
- Libe R., Fratticci A., Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14:13-28.
- Haluska P., Worden F., Olmos D., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73.
Arquivos suplementares
